Contact: h.e.oakervee@qmul.ac.uk

Professional interests

Heather Oakervee joined the Institute of Cancer in June 2005 having trained in Haematology at Barts and the London from 1997 and completed her MD in the department. Her main clinical and research interest is multiple myeloma and has been involved in many clinical trials of the new agents recently introduced in myeloma and optimising their use. Her main work now comprises early phase clinical trials, in particular in myeloma and also in trial management.

Recent Publications:

• Sirohi B, Powles R, Cavenagh J, Oakervee H, Dyer P, Rintala T, Kulkarni S, Rudin C, Treleaven J, Morgan G. Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy. Hematology 2007;12(2):113-5
• Greaves P, Oakervee H, Kaya B, Farah N. Posterior reversible encephalopathy syndrome following anti-lymphocyte globulin treatment for severe aplastic anaemia. Br Journal Haematol 2006;134(3):251
• Davies JK, Taussig DC, Oakervee H, Davies AJ, Agrawal SG, Gribben JG, Lister TA, Cavenegh JD. Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. J Clin Oncol 2006;24(14):e23-5
• Popat R, Joel S, Oakervee H, Cavenagh J. Bortezomib for multiple myeloma. Exp Opin Pharmacother 2006;7(10):1337-46
• Bhattacharyya M, Oakervee H, Dalley C, Glynn M, Cavenagh J. Hepatitis-associated aplastic anaemia treated successfully with antilymphocyte globulin. Clin Lab Haematol 2005;27(5):331-3
• Kaya B, Davies CEF, Oakervee HE, Silver NC, Gawler J, Cavenagh JD. Guillain Barre syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia. J Clin Path 2005;58(9):994-5.
• Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine, DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129(6):755-62
• Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett MJ, Rohatiner AZS, Lister TA, Cavenagh JD, Hinds CJ. Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia 2005;60(4):340-7.
• Popat R, Oakervee H, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Am J Oncol Review 2005;4(12):750-756
• Popat R, Oakervee H, Cavenagh J. Bortezomib combination therapy for multiple myeloma. Br J Cancer Management 2005;2(2)17-19
• Cavenagh JD & Oakervee HE on behalf of the British Committee for Standards in Haematology. Thalidomide in Multiple Myeloma: Current Status and Future prospects. Br J Haematol 2003;120(1):18-26
• Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK Myeloma Forum Phase II Study of Thalidomide; Long term follow-up and recommendations for treatment. Leuk Res 2003;27(10):909-14.
• Taussig DC, Davies AJ, Cavenagh JD, Oakervee HE, Syndercombe-Court YD, Kelsey SM, Amess JA, Rohatiner AZS, Lister TA, Barnett MJ. Durable remissions of myelodysplastic syndrome and acute myeloid leukaemia after reduced-intensity allografting. J Clin Oncol 2003;21(16):3060-65
• Oakervee HE, Cavenagh JD. Thalidomide: Its use in Haematological Malignancies. Cancer Topics 2003;12(1):5-8
  

<< Return to staff list